Download
41746_2024_Article_1021.pdf 1,27MB
WeightNameValue
1000 Titel
  • Beyond the 510(k): The regulation of novel moderate-risk medical devices, intellectual property considerations, and innovation incentives in the FDA’s De Novo pathway
1000 Autor/in
  1. Aboy, Mateo |
  2. Crespo, Cristina |
  3. Stern, Ariel Dora |
1000 Verlag
  • Nature Publishing Group UK
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-02-08
1000 Erschienen in
1000 Quellenangabe
  • 7(1):29
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41746-024-01021-y |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10853500/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:p>Moderate-risk medical devices constitute 99% of those that have been regulated by the U.S. Food and Drug Administration (FDA) since it gained authority to regulate medical technology nearly five decades ago. This article presents an analysis of the interaction between the 510(k) process —the historically dominant path to market for most medical devices— and the De Novo pathway, a more recent alternative that targets more novel devices, including those involving new technologies, diagnostics, hardware, and software. The De Novo pathway holds significant potential for innovators seeking to define new categories of medical devices, as it represents a less burdensome approach than would have otherwise been needed historically. Moreover, it supports the FDA in its effort to modernize the long-established 510(k) pathway by promoting the availability of up-to-date device “predicates” upon which subsequent device applications can be based, reflecting positive spillovers that are likely to encourage manufacturers to adopt current state-of-the-art technologies and modern standards of safety and effectiveness. We analyze the of characteristics all the De Novo classification requests to date, including the submission type, trends, FDA review times, and device types. After characterizing how the De Novo process has been used over time, we discuss its unique challenges and opportunities with respect to medical device software and AI-enabled devices, including considerations for intellectual property, innovation, and competition economics.</jats:p>
1000 Sacherschließung
lokal Article
lokal /706/648/270
lokal /706/703/559
lokal article
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-5168-4321|https://frl.publisso.de/adhoc/uri/Q3Jlc3BvLCBDcmlzdGluYQ==|https://orcid.org/0000-0002-3586-1041
1000 Hinweis
  • DeepGreen-ID: 0fc59e663c3841c19a1bb98774a1fcec ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Novo Nordisk Fonden |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Novo Nordisk Fonden |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6493500.rdf
1000 Erstellt am 2025-02-03T20:54:55.569+0100
1000 Erstellt von 322
1000 beschreibt frl:6493500
1000 Zuletzt bearbeitet 2025-07-30T08:50:31.565+0200
1000 Objekt bearb. Wed Jul 30 08:50:31 CEST 2025
1000 Vgl. frl:6493500
1000 Oai Id
  1. oai:frl.publisso.de:frl:6493500 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source